Achievement and maintenance of therapeutic response to brodalumab in patients with moderate-to-severe plaque psoriasis: An Italian, observational, retrospective and prospective study (BRIGHT study)

被引：0

作者：

Dapavo, Paolo ^{[1
]}

Fabbrocini, Gabriella ^{[2
]}

Campione, Elena ^{[3
]}

Giofre, Claudia ^{[4
]}

Balato, Anna ^{[5
]}

Potenza, Concetta ^{[6
]}

Dastoli, Stefano ^{[7
]}

Malagoli, Piergiorgio ^{[8
]}

Offidani, Annamaria ^{[9
]}

Bardazzi, Federico ^{[10
]}

Peris, Ketty ^{[11
]}

Pella, Paolo ^{[12
]}

De Pasquale, Rocco ^{[13
]}

Bonifati, Claudio ^{[14
]}

Giacchetti, Alfredo ^{[15
]}

Pallotta, Sabatino ^{[16
]}

Congedo, Maurizio ^{[17
]}

Amerio, Paolo ^{[18
]}

Fargnoli, Maria Concetta ^{[19
,20
]}

Pinton, Piergiacomo Calzavara ^{[21
]}

Venturini, Marina ^{[21
]}

机构：

[1] AOU Citta Salute & Sci PO Molinette, SC Dermatol, Turin, Italy

[2] AOU Federico II, AOU Federico 2, Naples, Italy

[3] UOSD Dermatol, Policlin Tor Vergata, Rome, Italy

[4] Azienda Osped Papardo, U O C Dermatol, Messina, Italy

[5] Clin Dermatolog, Policlin Luigi Vanvitelli, Naples, Italy

[6] Osped A Fiorini, UOC Dermatol Univ, Terracina, Italy

[7] UO Dermatol, AOU Mater Domini, Catanzaro, Italy

[8] Dermatol, Policlin San Donato, San Donato Milanese, Italy

[9] SOD Clin Dermatolog, AOU Riuniti Umberto Lancisi Salesi 1, Ancona, Italy

[10] UO Dermatol, AOU Policlin S Orsola Malpighi, Bologna, Italy

[11] Fdn Policlin Univ A Gemelli, UOC Dermatol, Rome, Italy

[12] Osped Infermi, SSD Dermatol, Ponderano, Italy

[13] AOU Policlin Vittorio Emanuele PO SMarco, Dermatol, Catania, Italy

[14] Ist Dermatol S Maria & S Gallicano, Dermatol, Rome, Italy

[15] UOC Dermatol, INRCA, RCA, Ancona, Italy

[16] V Div Dermatolog, IDI, Rome, Italy

[17] Osped Vito Fazzi, UO Dermatol, Lecce, Italy

[18] Univ Adriat G Annunziodi Chieti & Pescara, Ctr Ric Clin CAST, Chieti, Italy

[19] Univ Laquila, Dipartimento Sci Clin Applicate & Biotecnolog, Laquila, Italy

[20] Osped San Salvatore, Unita Dermatol, Laquila, Italy

[21] ASST Spedali Civili, UOC Dermatol, Piazzale Spedali Civili 1, Brescia, Italy

来源：

JEADV CLINICAL PRACTICE | 2023年 / 2卷 / 04期

关键词：

brodalumab; effectiveness; observational; psoriasis; real-world; QUALITY-OF-LIFE; INDEX PASI; AREA; AGENTS;

D O I：

10.1002/jvc2.204

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

BackgroundBrodalumab, a fully human anti-interleukin (IL)-17 monoclonal antibody that blocks IL-17RA, is approved in Europe for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic treatment.ObjectivesThis study evaluated the achievement and maintenance of therapeutic response for 1 year in psoriasis patients treated with brodalumab in the Italian clinical practice.MethodsReal-world, multicenter, observational, retrospective and prospective study. The retrospective phase ranged from enrolment visit to initiation of brodalumab (12 +/- 4 weeks before). The prospective phase ranged from enrolment to a routine follow-up visit set after 52 +/- 4 weeks.ResultsOne hundred eighty-four patients were eligible and 164 completed the observation period (median 11.9 months; Q1-Q3: 11.4-12.3). At enrolment, the mean duration of disease was 13.9 years (standard deviation; 13.3), 94% of patients (N = 172) had >= 1 clinical manifestation of psoriasis, mainly erythema and itching, and 95.6% had received >= 1 antipsoriatic treatment before brodalumab. Patients who reached an absolute Psoriasis Area and Severity Index (PASI) score <= 3 at week 12 and maintained it <= 3 through week 52 were 97 (64.7%). At week 12, 72.7% of patients achieved PASI 75, 54.5% PASI 90 and 42.0% PASI 100. At Week 52, 92.9% of patients achieved PASI 75, 84.4% PASI 90 and 61.7% PASI 100. A static Physician's Global Assessment (sPGA) score = 0 was obtained by 55.0% of patients after 12 weeks of brodalumab and by 77.0% after 52 weeks. A Dermatology Life Quality Index <= 1 was reported by 71.9% of patients after 12 weeks and by 89.9% after 52 weeks of treatment. No significant outcome differences were shown among patient subgroups defined by previous antipsoriatic treatments (none, systemic other than biologics or biologic) at either brodalumab initiation or any of the subsequent study visits.ConclusionsIn this real-world setting, brodalumab was rapidly effective on skin lesions and quality of life both in biologic-na & iuml;ve and biologic-experienced moderate-to-severe psoriasis patients, with a favourable safety profile. image

引用

页码：739 / 752

页数：14

共 33 条

[1] Comparison of Biologics and Oral Treatments for Plaque Psoriasis A Meta-analysis [J].

Armstrong, April W. ;

Puig, Luis ;

Joshi, Avani ;

Skup, Martha ;

Williams, David ;

Li, Junlong ;

Betts, Keith A. ;

Augustin, Matthias .

JAMA DERMATOLOGY, 2020, 156 (03) :258-269

[2] Patient-Reported Outcome Measures as Complementary Information to Clinician-Reported Outcome Measures in Patients With Psoriasis [J].

Barbieri, John S. ;

Gelfand, Joel M. .

JAMA DERMATOLOGY, 2021, 157 (10) :1236-1237

[3] Correlation between trough serum levels of adalimumab and absolute PASI score in a series of patients with psoriasis [J].

Carrascosa, J. M. ;

Toro Montecinos, M. ;

Ballesca, F. ;

Teniente Serra, A. ;

Martinez Caceres, E. ;

Ferrandiz, C. .

JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 (02) :140-144

[4] PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis [J].

Carrera, Carlo Giovanni ;

Dapavo, Paolo ;

Malagoli, Piergiorgio ;

Naldi, Luigi ;

Arancio, Luisa ;

Gaiani, Francesca ;

Egan, Colin Gerard ;

Di Mercurio, Marco ;

Cattaneo, Angelo .

JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 (05) :481-486

[5] Redefining the therapeutic objective in psoriatic patients candidates for biological therapy [J].

Carretero, G. ;

Puig, L. ;

Carrascosa, J. M. ;

Ferrandiz, L. ;

Ruiz-Villaverde, R. ;

de la Cueva, P. ;

Belinchon, I. ;

Vilarrasa, E. ;

del Rio, R. ;

Sanchez-Carazo, J. L. ;

Lopez-Ferrer, A. ;

Peral, F. ;

Armesto, S. ;

Eiris, N. ;

Mitxelena, J. ;

Vilar-Alejo, J. ;

Martin, M. A. ;

Soria, C. .

JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 (04) :334-346

[6] Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis [J].

Egeberg, A. ;

Andersen, Y. M. F. ;

Halling-Overgaard, A-S ;

Alignahi, F. ;

Thyssen, J. P. ;

Burge, R. ;

Mallbris, L. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (01) :39-46

[7] Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials [J].

Elewski, Boni ;

Rich, Phoebe ;

Lain, Edward ;

Soung, Jennifer ;

Lewitt, George Michael ;

Jacobson, Abby .

JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (01) :261-265

[8] Brodalumab: A new way to inhibit IL-17 in psoriasis [J].

Facheris, Paola ;

Valenti, Mario ;

Pavia, Giulia ;

Guanziroli, Elena ;

Narcisi, Alessandra ;

Borroni, Riccardo G. ;

Costanzo, Antonio .

DERMATOLOGIC THERAPY, 2020, 33 (03)

[9] Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience [J].

Fargnoli, M. C. ;

Esposito, M. ;

Dapavo, P. ;

Parodi, A. ;

Rossi, M. ;

Tiberio, R. ;

Dastoli, S. ;

Offidani, A. M. ;

Argenziano, G. ;

Gisondi, P. ;

Lo Schiavo, A. ;

Loconsole, F. ;

Pella, P. ;

Bardazzi, F. ;

Cusano, F. ;

Gattoni, M. ;

Nacca, M. ;

Cannavo, S. P. ;

Pellegrini, C. ;

Costanzo, A. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (03) :693-700

[10] Brodalumab: Efficacy, safety, and survival in mid-term (52 weeks) on real clinical practice in Andalucia, Spain [J].

Galan-Gutierrez, Manuel ;

Font-Ugalde, Pilar ;

Padial, Elena ;

Hernandez-Montoya, Carlos ;

Godoy, Daniel ;

Armario-Hita, Jose C. ;

Ruiz-Villaverde, Ricardo .

INTERNATIONAL JOURNAL OF DERMATOLOGY, 2023, 62 (05) :700-706

← 1 2 3 4 →